Compare Merck & Co., Inc. (MRK) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Upstart Holdings Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Upstart Holdings Inc trades at $26.01 (market cap $2.63B). The key difference: Merck & Co., Inc. is far larger — about 139.3× Upstart Holdings Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| MRK | UPST | |
|---|---|---|
Market Cap | $366.28B | $2.63B |
Sector | Health | Financials |
52-Week High | $156.43 | $68.11 |
52-Week Low | $77.60 | $24.22 |
Enterprise Value | $413.04B | — |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
Upstart Holdings (UPST) trades at $26.98, down 3.81% on the day, reflecting recent bearish momentum amid mixed earnings performance. The stock shows oversold technical signals with an RSI of 18.98, while fundamentals highlight a return to profitability in 2025 with net income of $53.60M on $1.02B revenue. Recent news indicates strategic refocus on personal loans and AI-driven lending growth, though cash flow volatility and high debt levels pose concerns. Analyst consensus remains divided with a $45.00 price target suggesting significant upside potential from current levels.
The outlook for UPST hinges on execution in AI-powered lending expansion and margin improvement, with risks including consumer credit stress and competitive pressures. Institutional sentiment is cautiously optimistic, but investors should monitor debt management and quarterly earnings consistency for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
